Nexell's Baxter deal leaves it without future
This article was originally published in Clinica
Executive Summary
Lengthy and unsuccessful efforts to raise capital was one of the key reasons behind Nexell's decision last week to opt for closure. Staff posts will be cut to just three while the Irvine, California company progresses with an orderly wind down. Efforts to merge the company with a third party also proved fruitless. Finally, Nexell opted for the chosen course in order to preserve its assets and meet its obligations, said president and CEO William Albright.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.